This company has been marked as potentially delisted and may not be actively trading. OTCMKTS:DCTHD Delcath Systems (DCTHD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesBuy This Stock About Delcath Systems Stock (OTCMKTS:DCTHD) Get Delcath Systems alerts:Sign Up Key Stats Today's Range$9.76▼$10.0550-Day Range N/A52-Week Range$1.22▼$63,000.00Volume306,725 shsAverage Volume771 shsMarket Capitalization$394 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver. Read More Receive DCTHD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DCTHD Stock News HeadlinesH.C. Wainwright Sticks to Its Buy Rating for Delcath Systems (DCTH)May 29, 2026 | theglobeandmail.comDelcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress AbstractsMay 26, 2026 | finance.yahoo.comSpaceX will crumble without these 5 companiesThe SpaceX IPO is drawing near, but the real opportunity may lie in 5 lesser-known companies providing the critical infrastructure SpaceX depends on to operate. Goldman Sachs and Morgan Stanley are reportedly already building positions in one of these names. Another is a resource miner that Elon Musk's broader empire - including Tesla - relies on. Lance Ippolito has detailed all five inside his free SpaceX Investing Blackbook.June 20 at 1:00 AM | InvestPub (Ad)How The Delcath Systems (DCTH) Story Is Shifting With Hepzato Milestones And 2026 GuidanceMay 1, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: CervoMed (CRVO) and Delcath Systems (DCTH)April 26, 2026 | theglobeandmail.comDelcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN ...April 6, 2026 | finance.yahoo.comDoes The Market Have A Low Tolerance For Delcath Systems, Inc.'s (NASDAQ:DCTH) Mixed Fundamentals?February 15, 2026 | finance.yahoo.comClear Street Raises Delcath Systems, Inc. (DCTH) Target to $29, Maintains Buy RatingFebruary 11, 2026 | finance.yahoo.comSee More Headlines DCTHD Stock Analysis - Frequently Asked Questions How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (OTCMKTS:DCTHD) posted its quarterly earnings results on Friday, November, 11th. The medical device company reported ($231.00) earnings per share for the quarter, topping the consensus estimate of ($1,151.50) by $920.50. The medical device company earned $0.44 million during the quarter. When did Delcath Systems' stock split? Delcath Systems's stock reverse split before market open on Monday, November 6th 2017.The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 3rd 2017. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. Company Calendar Last Earnings11/11/2016Today6/20/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolOTCMKTS:DCTHD Previous SymbolNASDAQ:DCTH CIKN/A Webwww.delcath.com Phone212-489-2100FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.22 million Net Margins-1,546.38% Pretax MarginN/A Return on EquityN/A Return on Assets-343.56% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.50 Sales & Book Value Annual Sales$3.41 million Price / Sales0.12 Cash FlowN/A Price / Cash FlowN/A Book Value($1,036.00) per share Price / Book-0.01Miscellaneous Outstanding Shares40,000Free FloatN/AMarket Cap$394 thousand OptionableNot Optionable Beta-0.03 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:DCTHD) was last updated on 6/20/2026 by MarketBeat.com Staff. From Our PartnersBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredAn Elon Musk Fan's Warning About SPCXJon Najarian called Tesla in 2014 when legacy automakers dismissed it. Now he's warning investors to skip SPCX...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Delcath Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
